6 June 2017

Holding(s) in Company

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES(i)

Read more

6 June 2017

Holding(s) in Company

 

Read more

30 May 2017

Holding(s) in Company

 

Read more

30 May 2017

Holding(s) in Company

 

Read more

25 May 2017

Holding(s) in Company

 

Read more

23 May 2017

Holding(s) in Company

Read more

16 May 2017

Partial Exercise of Over-Allotment Option

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014

Read more

9 May 2017

Holding(s) in Company

 

Read more

8 May 2017

Holding(s) in Company

 

Read more

5 May 2017

Holding(s) in Company



Read more

Targeting unmet needs

384m people worldwide suffer from COPD and 37 years is the median life expectancy of CF patients

Read more about COPD and CF in the unmet needs section of this website

Go

Basic & Clinical Pharmacology & Toxicology

Peer-reviewed publication on dual PDE3/4 inhibitors as novel treatments for COPD

The Lancet Respiratory Medicine

Peer-reviewed paper in the Lancet's highly-respected medication journal

Close

Verona Pharma plc
3 More London Riverside, London SE1 2RE
T: +44 (0)203 283 4200

Linkedin     Email Us